MedTrace Logo

Sorafenib With TACE to Treat Hepatocellular Carcinoma

NCT00478374 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 21

Last updated 2010-11-02

No results posted yet for this study

Summary

The purpose of this study is to determine the feasibility to combine sorafenib with transarterial chemoembolisation in patients suffering from hepatocellular carcinoma.The hypothesis is that sorafenib may prevent the development and growth of tumoral lesions not treated by chemoembolisation.

Conditions

Interventions

DRUG

Sorafenib

Sorafenib 400mg bid

PROCEDURE

Transarterial chemoembolisation with doxorubicin

Transarterial chemoembolisation (TACE)

Sponsors & Collaborators

  • University of Bern

    lead OTHER

Principal Investigators

  • Daniel Candinas · Inselspital

  • Markus Borner · Inselspital

  • Jean-François J Dufour, MD · Inselspital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-05-31
Primary Completion
2009-01-31
Completion
2009-01-31

Countries

  • Switzerland

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00478374 on ClinicalTrials.gov